Filing Details
- Accession Number:
- 0001179110-14-016923
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-11-21 20:00:16
- Reporting Period:
- 2014-11-19
- Filing Date:
- 2014-11-21
- Accepted Time:
- 2014-11-21 20:00:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1005201 | Depomed Inc | DEPO | Pharmaceutical Preparations (2834) | 943229046 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1367754 | M Matthew Gosling | C/O Depomed, Inc. 7999 Gateway Boulevard, Suite 300 Newark CA 94560 | Senior Vp, General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-11-19 | 71,000 | $6.17 | 88,211 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-11-19 | 71,000 | $15.36 | 17,211 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options | Acquisiton | 2014-11-19 | 71,000 | $0.00 | 71,000 | $6.17 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2016-06-26 | No | 4 | M | Direct |
Footnotes
- Vested and became exercisable as to 25% of the underlying shares on the first anniversary of the grant date (June 26, 2006) and as to the remaining shares in equal monthly installments over 36 months.
- The price reported is a weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each price within the range set forth in this footnote.
- The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Billionaire Hedge Funds
